Status: Not yet recruiting
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
Participants needed: 16
Trial details
Phase: Phase 2Age: 18-74Biological sex: AllType: InterventionalSponsor: GenfitUpdated: Jul 9, 2026
Eligibility criteria
Participants with liver cirrhosis of any underlying etiology (liver cirrhosis di... [+4]
Known hypersensitivity to nitazoxanide or any known excipient of the IMP [+11]